Management of Cardiogenic Pulmonary Edema (RENAU-OAP)

Sponsor
Centre Hospitalier Annecy Genevois (Other)
Overall Status
Terminated
CT.gov ID
NCT03148847
Collaborator
(none)
859
1
36
23.9

Study Details

Study Description

Brief Summary

The prevalence of heart failure is estimated to 2.3 percent of the adult population and strongly increases with age, according to french disability-health surveys. In France, more than 32,000 annual deaths are attributable to heart failure and the five-year survival rate is similar to those found in many cancers. A better therapeutic management (angiotensin converting enzyme inhibitor and beta-blockers) helped reduce mortality after an episode of heart failure requiring hospitalization, but, nevertheless it remains high.

The severity of cardiogenic pulmonary edema depends on several factors such as etiology, hemodynamic status, effect on hematosis, and fatigue.

It is important to note that cardiogenic pulmonary edema initial management is decisive. In addition, early and adapted management of cardiogenic pulmonary edema is associated with a shorter hospital stay and reduced hospital mortality.

The Coronary Emergency Network (RESURCOR) within the Northern French Alps Emergency Network (RENAU) is an emergency care system structured in the departments of Isère, Savoie and Haute Savoie. Its main goal is to help improve emergency management by using regional good practice guidelines (www.renau.org). In this context, projects aiming to evaluate professional practices are developed regularly. Since emergency management of cardiogenic pulmonary edema has not been evaluated, the Northern French Alps Emergency Network offers an approach to improve professional practices by defining and disseminating guidelines on cardiogenic pulmonary edema management which will then be assessed.

Condition or Disease Intervention/Treatment Phase
  • Other: Baseline care
  • Other: Referential's dissemination

Detailed Description

The prevalence of heart failure is estimated to 2.3 percent of the adult population and strongly increases with age, according to disability-health surveys in France. In recent years, effective treatments (revascularization in percutaneous coronary intervention, circulatory assistance) helped reduce mortality in post-myocardial infarction, which combined with the increase of life expectancy has led to an increase number of patients with chronic heart failure. More than 32,000 annual deaths are attributable to heart failure and the five-year survival rate is similar to those found in cancers of the breast, bladder, colon, ovarian, and prostate. A better therapeutic management (angiotensin converting enzyme inhibitor and beta-blockers) helped reduce mortality after an episode of heart failure requiring hospitalization, but, nevertheless it remains high.

Main clinical manifestations are those of left heart failure, such as cardiogenic pulmonary edema which is a medical emergency. Treatment must take into account pathophysiological aspects of heart failure, etiologies of cardiogenic pulmonary edema and any potential factors or triggers apart from general measures. Two consensus statements and an international recommendation help define therapeutic strategies in this particular situation.

Signs suggestive of cardiogenic pulmonary edema include orthopnea, bilateral crackles or wheezing (patients over 70 years without known asthma), edema of the lower limbs, and gallop sound on heart auscultation. The evolution of these signs makes it particularly possible to manage the response to the treatment. The severity of cardiogenic pulmonary edema depends on several factors such as etiology (ECG analysis and chest pain assessment for acute coronary syndrome), hemodynamic status (blood pressure, heart rate), effect on hematosis (cyanosis, oxygen saturation), and fatigue (low respiratory rate with persistent cardiogenic pulmonary edema signs). The respiratory rate represents a simple clinical feature that can be used to quantify dyspnea (sign of severity if greater than 30 per minute in adults) and then follow its evolution (improvement, exhaustion). Disorders of consciousness can testify to the severity of the hemodynamic state and/or exhaustion.

Cardiogenic pulmonary edema management without shock implies urgent administration of vasodilators (trinitrin) and intravenous loop diuretics in presence of congestion signs along with the establishment of a system of care adapted to severity (Emergency Mobile Services or ambulance, hospitalization in Intensive Care Unit, intensive cardiology unit, cardiology or medicine department, or emergency passage). The subsequent therapeutic management will especially depend on initial treatment by the primary care physician, so it is preferable to record doses and hours of medications. Non-hospitalization must remain exceptional for non-severe decompensation with rapidly favorable evolution.

The French Observatory of Acute Heart Failure (OFICA) including nearly 1,800 patients specified epidemiological and therapeutic data of patients hospitalized for cardiogenic pulmonary edema in 2009. However, this study did not describe the initial management of the Mobile Emergency and Resuscitation Service and emergency services of hospitals. It is important to note that cardiogenic pulmonary edema initial management is decisive. In addition, early and adapted management of cardiogenic pulmonary edema is associated with a shorter hospital stay and reduced hospital mortality.

The Coronary Emergency Network (RESURCOR) within the Northern French Alps Emergency Network (RENAU) is an emergency care system structured in the departments of Isère, Savoie and Haute-Savoie. Its main goal is to help improve emergency management by using regional good practice guidelines (www.renau.org). In this context, projects aiming to evaluate professional practices are developed regularly. Since emergency management of cardiogenic pulmonary edema has not been evaluated, the Northern French Alps Emergency Network offers an approach to improve professional practices by defining and disseminating a guideline on cardiogenic pulmonary edema management which will then be assessed.

Study Design

Study Type:
Observational
Actual Enrollment :
859 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Evaluation of Professional Practices on the Management of Cardiogenic Pulmonary Edema (RENAU-OAP)
Actual Study Start Date :
Jan 1, 2015
Actual Primary Completion Date :
Dec 1, 2016
Actual Study Completion Date :
Jan 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Baseline care

Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013

Other: Baseline care

Referential's dissemination

Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure

Other: Referential's dissemination

Outcome Measures

Primary Outcome Measures

  1. Change of quality of initial care of patients with cardiogenic pulmonary edema after dissemination of good practice standards [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    Two kinds of predefined quality indicators will be evaluated at different stages of care and compared among the two periods, before and after dissemination of good practice standards, looking for informations in medical charts during the management of patients either care by Mobile Emergency and Resuscitation Services or at emergency departments and in mails at time of hospital discharge).

Secondary Outcome Measures

  1. Patients' description at the onset of cardiogenic pulmonary edema (clinical) [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    Clinical characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).

  2. Patients' description at the onset of cardiogenic pulmonary edema (biological) [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    Biological characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).

  3. Patients' description at the onset of cardiogenic pulmonary edema (radiological) [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    Radiological characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).

  4. Patients' description at the onset of cardiogenic pulmonary edema (echocardiographic) [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    Echocardiographic characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).

  5. Mortality of patients hospitalized for cardiogenic pulmonary edema [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    number of patients dying during hospitalization for cardiogenic pulmonary edema

  6. Needs for Hospitalization in intensive care units [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    number (and rate) of patients with cardiogenic pulmonary edema, requiring hospitalization in intensive care unit

  7. Needs for respiratory assistance [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    number of patients and kind of respiratory assistance for patients with cardiogenic pulmonary edema

  8. Inter-services transfers [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    number of patients who require transfers from an emergency room (or a cardiology ward) to intensive care units and vice-versa

  9. Length of stay in hospital [an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)]

    number of days between arrival and discharge

  10. Re-hospitalizations during the first six months [up to six months]

    number of re-hospitalizations during the first six months after the onset of cardiogenic pulmonary edema

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥18 years old

  • hospitalization during one of the two designed period (either year 2013, or year 2017) in a center belonging to Northern French Alps Emergency Network

  • diagnosis of cardiogenic pulmonary edema, or heart failure (either left-sided, congestive or unspecified)

Exclusion Criteria:
  • people who refuse to have their health information used will not be included

  • people whose care will have begun in a center not belonging to the Northern French Alps Emergency Network

Contacts and Locations

Locations

Site City State Country Postal Code
1 CH Annecy Genevois Pringy France F-74374

Sponsors and Collaborators

  • Centre Hospitalier Annecy Genevois

Investigators

  • Study Chair: Loic BELLE, MD, Centre Hospitalier Annecy Genevois

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Centre Hospitalier Annecy Genevois
ClinicalTrials.gov Identifier:
NCT03148847
Other Study ID Numbers:
  • 2014-RENAU-1
First Posted:
May 11, 2017
Last Update Posted:
Jun 18, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2019